Merck & Co., Inc. $MRK Stock Holdings Lifted by Trivium Point Advisory LLC

Trivium Point Advisory LLC grew its position in Merck & Co., Inc. (NYSE:MRK) by 34.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,671 shares of the company’s stock after purchasing an additional 4,570 shares during the period. Trivium Point Advisory LLC’s holdings in Merck & Co., Inc. were worth $2,271,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Kingdom Financial Group LLC. bought a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $25,000. Abound Financial LLC bought a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $26,000. Prosperity Bancshares Inc bought a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $26,000. High Note Wealth LLC raised its position in Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after acquiring an additional 109 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at approximately $31,000. 76.07% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Stock Performance

MRK opened at $150.67 on Tuesday. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The stock’s 50 day moving average price is $128.81 and its two-hundred day moving average price is $121.53. The firm has a market capitalization of $371.73 billion, a P/E ratio of 120.54, a price-to-earnings-growth ratio of 6.40 and a beta of 0.19. Merck & Co., Inc. has a 12-month low of $77.58 and a 12-month high of $154.49.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The company had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. During the same period in the previous year, the company earned $2.13 earnings per share. The company’s quarterly revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities analysts forecast that Merck & Co., Inc. will post 2.76 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.3%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio is presently 272.00%.

Wall Street Analyst Weigh In

Several analysts have commented on MRK shares. Weiss Ratings downgraded shares of Merck & Co., Inc. from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, August 11th. UBS Group lifted their price objective on shares of Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Barclays upped their price objective on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Royal Bank Of Canada lowered Merck & Co., Inc. from an “outperform” rating to a “sector perform” rating and raised their target price for the company from $142.00 to $150.00 in a report on Thursday, August 20th. Finally, Wells Fargo & Company boosted their price target on Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 8th. Fifteen investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $144.10.

Insider Transactions at Merck & Co., Inc.

In other news, EVP Jennifer Zachary sold 80,315 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the transaction, the executive vice president owned 45,509 shares of the company’s stock, valued at approximately $6,073,631.14. This represents a 63.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP David Michael Williams sold 52,847 shares of the stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the sale, the executive vice president owned 31,716 shares of the company’s stock, valued at approximately $4,084,069.32. The trade was a 62.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 228,238 shares of company stock worth $29,977,783. 0.17% of the stock is currently owned by insiders.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.